Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 824 across all filing types
Latest filing 2023-11-13 Report Publication Anno…
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Reports 2023 Third Quarter Financial Results
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (under 2,000 characters) submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Kamada Reports Significant Increase in Sales and Profitability...' and provides a filename for the attachment. Following the 'Menu vs Meal' rule, this is an announcement of a report publication rather than the financial report itself.
2023-11-13 English
The company's financial results for the Third quarter 2023 were published abroad
Regulatory Filings
2023-11-13 Hebrew (modern)
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
Earnings Release Classification · 1% confidence The document is a Form 6-K filed with the SEC by a Foreign Private Issuer (Kamada Ltd.). The core content, attached as Exhibit 99.1, is an announcement stating that the company 'will release financial results for the third quarter and first nine months ended September 30, 2023' and will 'host an investment community conference call' on November 13, 2023. This document itself is not the full financial report (10-K or IR) nor the transcript (CT), but rather the initial public announcement regarding the upcoming release of earnings results and the associated conference call. This aligns best with the Earnings Release (ER) definition, which covers the initial announcement of periodical financial results (key highlights are usually included or referenced, and the call is the primary mechanism for discussion). Although it is filed on Form 6-K, the *purpose* of the filing is to announce earnings. 9M 2023
2023-11-08 English
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (2006 chars) from KAMADA LTD, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The title explicitly states: "Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023". Crucially, the text includes the line: "Attached hereto is a report on... *ea187904-6k_kamadaltdEDGAR1_Bannerless_isa.pdf*". This structure—an announcement about the release of financial results (Q3/Nine Months) and an attached PDF—fits the definition of a Report Publication Announcement (RPA) rather than the full Earnings Release (ER) or Interim Report (IR) itself, adhering to the 'MENU VS MEAL' rule.
2023-11-08 English
Announces Recent Achievements with CYTOGAM
Regulatory Filings Classification · 1% confidence The document explicitly identifies itself as a "FORM 6-K" filed with the SEC, which is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934' for the month of October 2023. Form 6-K filings are generally used to report material information that a foreign private issuer is required to disclose to its home country's securities regulator or stock exchange, or that it makes public in its home country. This type of filing does not directly map to the provided specific codes like 10-K (Annual Report) or ER (Earnings Release). Since Form 6-K is a mandatory regulatory filing that doesn't fit the other specific categories (like AGM-R, CT, DIRS, etc.), the most appropriate fallback category is 'Regulatory Filings' (RNS), as it covers general regulatory announcements that don't fit elsewhere, especially for non-US specific forms like 6-K.
2023-10-16 English
Announces Recent Achievements with CYTOGAM
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states: "Attached hereto is a report on*Kamada Announces Recent Achievements with CYTOGAM...*" and references an attached PDF file. The document itself is very short (2051 characters) and serves primarily to announce the publication of another document, rather than containing the full content of an Annual Report (10-K) or Interim Report (IR). This structure strongly indicates a Report Publication Announcement (RPA).
2023-10-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.